miR-630 downregulation promoted ERK activation through YAP1 upregulation, resulting in TKI resistance (Wu et al., 2018), and miR-135 down-regulates CDH1 and β-catenin and upregulates PD-L1 by targeting TRIM16, promoting drug resistance of NSCLC cells to gefitinib (Wang and Zhang, 2018). Here, CD274 is linked to non-small cell lung carcinoma.